XML 38 R25.htm IDEA: XBRL DOCUMENT

Revenue from Contracts with Customers (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of Contract Assets and Contract Liabilities

Total contract assets at March 31, 2022 were as follows:

(In thousands)	Contract Assets
Contract assets at December 31, 2021	$	13,363
Additions		11,451
Transferred to receivables, net		(4,602	)
Contract assets at March 31, 2022	$	20,212

Total contract liabilities at March 31, 2022 were as follows:

(In thousands)	Contract Liabilities
Contract liabilities at December 31, 2021	$	17,830
Additions		83
Amounts recognized into revenue		(3,063	)
Contract liabilities at March 31, 2022	$	14,850

Product sales, net

Schedule of Disaggregation of Revenues

During the three months ended March 31, 2022 and 2021, the Company recorded product sales, net, as follows:

	Three Months Ended March 31,
(In thousands)	2022		2021
VIVITROL	$	84,854	$	74,534
ARISTADA and ARISTADA INITIO		72,485		55,429
LYBALVI		13,929		—
Total product sales, net	$	171,268	$	129,963

Manufacturing and royalty revenues

Schedule of Disaggregation of Revenues

During the three months ended March 31, 2022 and 2021, the Company recorded manufacturing and royalty revenues as follows:

	Three Months Ended March 31, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products⁽¹⁾	$	—	$	37,054	$	37,054
VUMERITY		11,395		19,200		30,595
RISPERDAL CONSTA		15,578		1,848		17,426
Other		11,854		8,241		20,095
	$	38,827	$	66,343	$	105,170

	Three Months Ended March 31, 2021
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products⁽¹⁾	$	—	$	61,570	$	61,570
VUMERITY		2,448		10,992		13,440
RISPERDAL CONSTA		10,683		3,479		14,162
Other		11,954		18,721		30,675
	$	25,085	$	94,762	$	119,847

(1)

“Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate)